$22.67
4.69% today
Nasdaq, Apr 03, 06:45 pm CET
ISIN
US09062W2044
Symbol
BLFS

BioLife Solutions, Inc. Stock price

$23.78
-0.73 2.98% 1M
-0.51 2.10% 6M
-2.18 8.40% YTD
+6.18 35.11% 1Y
-0.42 1.74% 3Y
+14.32 151.37% 5Y
+22.21 1,414.65% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.95 4.16%
ISIN
US09062W2044
Symbol
BLFS
Sector

Key metrics

Market capitalization $1.12b
Enterprise Value $1.04b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 200.63
EV/Sales (TTM) EV/Sales 9.20
P/S ratio (TTM) P/S ratio 9.86
P/B ratio (TTM) P/B ratio 3.20
Revenue growth (TTM) Revenue growth -20.89%
Revenue (TTM) Revenue $113.34m
EBIT (operating result TTM) EBIT $-16.36m
Free Cash Flow (TTM) Free Cash Flow $5.20m
Cash position $104.58m
EPS (TTM) EPS $-0.26
P/E forward negative
P/S forward 11.52
EV/Sales forward 10.75
Short interest 10.86%
Show more

Is BioLife Solutions, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

BioLife Solutions, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a BioLife Solutions, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a BioLife Solutions, Inc. forecast:

Buy
100%

Financial data from BioLife Solutions, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
113 113
21% 21%
100%
- Direct Costs 59 59
42% 42%
52%
55 55
31% 31%
48%
- Selling and Administrative Expenses 53 53
22% 22%
47%
- Research and Development Expense 9.88 9.88
47% 47%
9%
-8.14 -8.14
82% 82%
-7%
- Depreciation and Amortization 8.22 8.22
36% 36%
7%
EBIT (Operating Income) EBIT -16 -16
72% 72%
-14%
Net Profit -11 -11
83% 83%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about BioLife Solutions, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioLife Solutions, Inc. Stock News

Neutral
PRNewsWire
16 days ago
BOTHELL, Wash. , March 18, 2025 /PRNewswire/ -- BioLife Solutions , Inc. (Nasdaq: BLFS ) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Cathy Coste to its board of directors, increasing board membership to seven.
Neutral
Seeking Alpha
about one month ago
BioLife Solutions, Inc. (BLFS) Q4 2024 Earnings Call Transcript
Neutral
PRNewsWire
about one month ago
Cell Processing revenue up 7%  sequentially to $20.3 million in the fourth quarter; 2024 Cell Processing revenue up 12%  over prior year to $73.5 million GAAP gross margin of 60%  and non-GAAP adjusted gross margin of 63%  for the fourth quarter GAAP net loss from continuing operations of $2.0 million and non-GAAP adjusted EBITDA of $4.0 million, or 18%  of total revenue for the fourth quarter ...
More BioLife Solutions, Inc. News

Company Profile

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.

Head office United States
CEO Roderick Greef
Employees 159
Founded 1987
Website www.biolifesolutions.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today